Cellectis S.A. (CLLS)
CLLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1627281/000119312526116428/0001193125-26-116428-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CLLS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2015 |
| SEC CIK | 0001627281 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.9M |
| Net income | -$67.6M |
| Operating income | -$33.1M |
| Net margin | -92.7% |
| Operating margin | -45.3% |
| Revenue growth | +75.8% |
| Cash | $61.5M |
| Total assets | $324.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Cibus' most recent financial statements included in its quarterly report on Form 10-Q for the quarter ended September 31, 2025 note that there is substantial doubt about Cibus' ability to continue as a going concern for at least one year from the date of issuance of those financial statements." | 20-F 2026-03-20 |
| Cash and burn | $61.5M cash; operating cash flow -$9.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG SA, Paris La Défense, France | PCAOB Form AP 2026-04-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $72.9M | -$67.6M | -$39.4M | $61.5M | No debt tags | $72.9M | 20-F 2026-03-20 |
| FY 2024 2024-12-31 | $41.5M | -$36.8M | $23.0M | $143.3M | No debt tags | $41.5M | 20-F 2026-03-20 |
| FY 2023 2023-12-31 | $755K | -$101.1M | -$24.7M | $136.7M | No debt tags | $755K | 20-F 2026-03-20 |
| FY 2022 2022-12-31 | $19.2M | -$106.1M | -$87.4M | $93.2M | No debt tags | $19.2M | 20-F 2025-03-14 |
| FY 2021 2021-12-31 | $30.3M | -$114.2M | -$104.6M | $185.6M | No debt tags | $30.3M | 20-F 2024-04-29 |
| FY 2020 2020-12-31 | $51.1M | -$81.1M | -$80.3M | $241.1M | No debt tags | $51.1M | 20-F 2023-03-14 |
| FY 2019 2019-12-31 | $15.2M | -$102.1M | -$69.1M | $340.5M | No debt tags | $15.2M | 20-F 2022-03-03 |
| FY 2018 2018-12-31 | $12.7M | -$78.7M | -$68.1M | $451.5M | No debt tags | $12.7M | 20-F 2021-03-04 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2025-07-02 |
| Latest annual report | 20-F | 2026-03-20 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 538 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.3% |
| 1 month | +7.3% |
| 3 months | -62.9% |
| Year to date | -75.6% |
| 1 year | -66.9% |
| From 52-week high | -77.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier